L

Leicester Royal Infirmary | Hope Trials Facility

Research site
(Unclaimed)
Location
Hope Trials Facility, Osborne Level 2, Leicester, Leicester, England
Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

51 of 276
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. (InMIND)

This is a Phase 3 double-blind, placebo-controlled, randomized study designed to investigate whether tafasitamab and lenalidomide as an add-on to rit...

Active, not recruiting
Marginal Zone Lymphoma
Follicular Lymphoma
Drug: rituximab
Drug: placebo

An open-label, single-arm, phase II, multicentre clinical trial to determine the rate of durable clinical benefit of nivolumab in patients with class...

Active, not recruiting
Colorectal Cancer
Drug: Nivolumab

Study GO43104 is a Phase III, randomized, open-label, multicenter study of lurbinectedin in combination with atezolizumab compared with atezolizumab...

Active, not recruiting
Small-Cell Lung Cancer
Drug: Etoposide
Drug: Atezolizumab

The purpose of this extension study is to provide continued treatment with Roche investigational medicinal product (IMP[s]) monotherapy or Roche IMP(...

Enrolling
Cancer
Drug: Ipatasertib
Locations recently updated

This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with end...

Enrolling
Early Breast Cancer
Drug: Endocrine Therapy of Physician's Choice
Drug: Abemaciclib

The purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombin...

Enrolling
Carcinoma, Non-small-Cell Lung
Drug: Amivantamab
Drug: Low Molecular Weight Heparin (LMWH)

First-in-human, open-label, sequential dose escalation and expansion study of CPI-0209 in patients with advanced solid tumors and lymphomas. CPI-0209...

Enrolling
Endometrial Cancer
Lymphoma, T-Cell
Drug: CPI-0209

This clinical trial is a Phase 2/3 study that will evaluate the efficacy and safety of etavopivat and test how well etavopivat works compared to plac...

Enrolling
Sickle Cell Disease
Drug: Placebo Tablets
Drug: Etavopivat Tablets High dose

The purpose of this study is to determine the safety, tolerability, maximum tolerated doses (MTDs) and recommended Phase 2 doses (RP2Ds) of JNJ-74856...

Active, not recruiting
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Drug: AZA
Drug: JNJ-74856665

The purpose of this study is to characterize safety and to determine the putative recommended Phase 2 dose(s) (RP2D[s]) and optimal dosing schedule(s...

Active, not recruiting
Lymphoma, Non-Hodgkin
Leukemia, Lymphocytic, Chronic, B-Cell
Drug: JNJ-75348780

This study aims to examine the efficacy and safety of obexelimab in participants with Warm Autoimmune Hemolytic Anemia (wAIHA).

Enrolling
Warm Autoimmune Hemolytic Anemia
Other: Placebo
Drug: Obexelimab

This study will be conducted in two parts. Part 1 will be the Dose Confirmation portion to determine recommended Phase 3 dose (RPTD) of venetoclax in...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Drug: CC-486
Drug: Venetoclax

The purpose of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL. Participants...

Enrolling
Leukemia, B-cell
Small Lymphocytic Lymphoma
Drug: Pirtobrutinib
Drug: Ibrutinib

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor,...

Enrolling
Non Small Cell Lung Cancer
Biological: Telisotuzumab Vedotin

Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to...

Enrolling
Relapsed/Refractory Multiple Myeloma
Drug: Dexamethasone
Drug: Daratumumab

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purpose of th...

Enrolling
Non-Hodgkin Lymphoma
Drug: CC-99282
Drug: Rituximab

The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide,...

Enrolling
Relapsed or Refractory Multiple Myeloma
Drug: Dexamethasone
Drug: Pomalidomide

The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinati...

Enrolling
Multiple Myeloma
Drug: Trametinib
Drug: Dexamethasone

The purpose of this study is to learn more about the safety and efficacy of tirzepatide compared to placebo in children or teenagers with type 2 diab...

Active, not recruiting
Type2 Diabetes
Glucose Metabolism Disorders
Drug: Placebo
Drug: Tirzepatide Dose 2

Researchers are looking for a better way to treat people who have macular edema secondary to retinal vein occlusion (RVO).In people with RVO, a blood...

Enrolling
Macular Edema Secondary to Retinal Vein Occlusion
Drug: Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose
Diagnostic Test: Fluorescein

Trial conditions

Lymphoma (34 trials)
Leukemia (22 trials)
Lung Cancer (16 trials)
Cancer (16 trials)
Central Nervous System C... (15 trials)
Multiple Myeloma (15 trials)
Nervous System Cancer (15 trials)
Non-Small-Cell Lung Carc... (15 trials)
Lymphoid Leukemia (12 trials)
Plasma Cell Cancer (12 trials)

And 90 more

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems